Official Title
Gout in French Polynesia: Epidemiology and Comorbidities, Genetic Causes and Prevalence of HLA B58:01
Brief Title
Epidemiology of Gout in French Polynesia
Protocol ID
NCT04812886
Lead Sponsor
Lille Catholic University
Brief Summary
Gout is a chronic disease caused by the deposit of monosodium urate (MSU) crystals in
body tissues secondary to hyperuricemia. Patients with gout suffer severe attacks of
acute joint pain. As the disease progresses, the joint pain becomes chronic and
associated with disabling and deformative manifestations called tophi. Gout is strongly
associated with various comorbidities including cardiovascular disease and chronic kidney
failure. Gout is a very common disease, affecting 0.9% of the adult population in France
and nearly 4% of the North-American population. Data from New Zealand show a particularly
high prevalence of gout among Polynesians (minority populations in New Zealand and other
islands of the South Pacific) that would be explained by genetic susceptibility and
frequently intertwined with metabolic diseases. Recent findings obtained from the
Polynesian population in New Caledonia disclose high prevalence figures close to 7%, a
level expected to be confirmed by an epidemiology study that will be conducted in
parallel with the present study and designed to determine the precise prevalence of gout
in French Polynesia and the most frequently associated genetic variants.
Detailed Description
International genomic studies conducted in populations with hyperuricemia and gout have
identified a number of associated alleles. The strength of the association between a
given allele and gout (or hyperuricemia) provides an indication of the importance of the
encoded protein in disease pathogenesis. It was in this way that the development of gout
was found to depend on renal urate transporters that were subsequently targeted by new
uricosuric therapies.
Overall, the search for gout-associated genes has mostly been done in the general
European population and revealed a small number of candidate loci. Most of these only
contribute a small amount to the heritability for gout susceptibility, suggesting that
additional genes and mechanisms of genetic influence are yet to be discovered. A common
feature of Genome-Wide Association studies done so far is that usually large sample sizes
are required in order to detect differences in allele frequencies and their contribution
to different traits between test groups. The Polynesian population of French Polynesia
possesses characteristics that make it particularly attractive to carry out
population-based genetic research. Historical records indicate that the Polynesians of
Tahiti and surrounding islands originate from a small founder population that has
undergone a number of bottlenecks, eventually becoming a genetically homogenous
population with a fairly high degree of consanguinity. The combination of a historic
founder event, continued isolation and recent expansion are all ideal properties for a
Genome Wide Association Study, as they ensure that 1) population stratification will be
easy to correct when performing association tests and 2) there are likely high-effect
variants that were kept at low frequency in mainland Europe due to negative selection but
rose to high frequencies in the Polynesians via the increase in genetic drift or
selection through adaptation to a specific environment and diet. Therefore, it is
plausible that rare variants with large effect on health-related quantitative traits may
be more easily detectable in Polynesians, even with much smaller sample sizes.
Study Period
-
Enrollment Count
1,088 participants
Eligibility Criteria
Inclusion Criteria:
- Living in Tahiti, Moorea, Tahaa-Raiatea, Tikehau, Nuku Hiva, Mangareva, Rurutu
- Agreeing to participate in the study
Exclusion Criteria:
- Homeless
- Living in communities (military camp, hospices, university residence, ...)
- Unable to answer questionnaires
- Under guardianship
Filters
Gout
NA
COMPLETED
ADULT
OLDER_ADULT